UCLA researchers in the Department of Neurology with an international team of scientists have developed several new molecular tweezer derivatives with novel synthesis methods that significantly improved the therapeutic efficacy and pharmacokinetic characteristics of the drug candidates.

UCLA researchers in the Department of Chemistry and Biochemistry have developed a novel method for high protein expression levels, in situ, involving RNA-based therapeutics.

Researchers in UCLA’s Department of Medicine have developed a novel peptide bridging technology that is a more efficient and cost-effective alternative to stapling technology for the manufacturing of peptide therapeutics. 

Researchers in UCLA Department of Dermatology have demonstrated through in vitro experiments that resveratrol, an ingredient in antioxidants and anti-aging products, generates sustained bactericidal and anti-inflammatory effects against P. acnes, the bacteria involved in the pathogenesis of acne.

UCLA researchers from the Department of Neurology have discovered a new class of drug candidates for Alzheimer’s disease. These small molecule compounds can specifically inhibit target enzymes to prevent target protein cleavage through an allosteric mechanism, preventing off-target side effect.

UCLA researchers under the guidance of Drs. Matthew Rettig and Mike Jung have developed a novel family of therapeutics for use against castration resistant prostate cancer. These drugs have been shown to inhibit the androgen receptor and are unaffected by the most common drug-resistant mutations found in prostate cancer patients.

UCLA researchers in the School of Medicine have developed a series of novel estrogen receptor antagonists for breast cancer therapy.

Researchers in UCLA Department of Molecular & Medical Pharmacology have used a rapid, live virus assay to develop potent enterovirus inhibitors.

Brief description not available

Brief description not available

UCLA researchers in the Department of Chemistry and Biochemistry have developed a novel trehalose hydrogel to help stabilize proteins for drug delivery.

Investigators at UCLA have discovered a series of small molecules to facilitate therapeutic exon skipping. The use of these identified molecules may enhance the effectiveness of antisense oligonucleotide agents currently in clinical development.

Brief description not available

Dr. Dimitrios Iliopoulos in UCLA Department of Medicine has identified a novel biomarker, microRNA-214 (miR-214), that predicts, at near 100% specificity, an ulcerative colitis patient’s risk for developing colon cancer.

UCLA researchers have invented a method of decreasing myocardial injury and infarct size through the intravenous administration of the netrin-1 or netrin-1-derived peptides during a cardiac event. These agents have powerful cardioprotective effects and provide a novel and effective therapy for the treatment of myocardial infarction.

UCLA has a robust intellectual property position on antibody-based diagnostics and therapeutics against N-cadherin for the treatment and detection of prostate and bladder cancers. The research and development leading to this promising technology has been conducted by Dr. Robert Reiter, Professor of Urology and Director of UCLA’s Prostate Cancer Program.

UCLA researchers in the Department of Medicine have discovered that administration of small molecule inhibitors of ENPP1 or functional antagonists of PPi can substantially attenuate ectopic calcification. This suggests that ENPP1 and PPi can be potential pharmacological targets when developing therapeutics for pathological ectopic calcification.

UCLA scientists have developed novel nanocapsules that facilitate efficient siRNA delivery into cells. The invention represents a significant advancement in realizing therapeutics based on targeted reduction of gene expression.  

UCLA Researchers in the Department of Chemistry & Biochemistry and School of Medicine have synthesized a series of small molecule therapeutics against GGTase-I and GGTase-II, both of which are critical oncology drug targets.

UCLA researchers in the Department of Neurology, and the Department of Chemistry & Biochemistry have developed small molecule inhibitors of both the neutral sphingomyelinase 2 (nSMase2) and acetylcholinesterase (AChE) as novel therapeutics for neurodegenerative disorders caused by protein aggregation.

UCLA researchers in the Department of Plastic Surgery and the School of Dentistry have developed a novel anti-osteoinflammatory agent for the prevention and suppression of arthritis disease progression.

UCLA researchers in the Departments of Neurology have developed a novel treatment for Lysosomal-storage diseases (LSDs) with neurological impairment.

Researchers from UCLA and RTI International have developed novel, small molecule agonists at cannabinoid type 1 and type 2 receptors (CB1R and CB2R) that have low blood-brain barrier (BBB) permeability.  The compounds represent promising therapeutics for treating chronic pain.   

UCLA Researchers have identified a novel pharmacological target for hematopoietic stem cell regeneration. They have developed small molecule inhibitors against the target and shown that the inhibitors cause rapid stem cell regeneration.

Brief description not available